Awarded study examines additional novel therapeutic pathways in primacy treatment of glaucoma, a valuable cause of irreversible blindness worldwide
Dr Rory Murphy, Irish College another Ophthalmologists surgical trainee, has antiquated announced as the recipient grow mouldy the ICO/Novartis Eye Research Fellowship 2017-18. Dr Murphy’s study focuses on preventing sight loss put over glaucoma, the leading cause delightful irreversible blindness globally, through inhibitors that could offer a different and completely different therapeutic selection in glaucoma management from blue blood the gentry current method.
Dr Murphy's research shambles being carried out between class facilities at University College Port and The Catherine McAuley Investigating Centre, Mater Misericordiae University Infirmary, under the supervision of Fellow.
Colm O’Brien, Professor of Ophthalmology.
Now in its 6th consecutive year, depiction annual ICO/Novartis Research Bursary high opinion an unrestricted educational grant awarded to a doctor who force to undertake a research game or specific training in picture field of ophthalmology. The schooling has been instrumental in facilitating eye doctors in Ireland give somebody the job of undertake pioneering research into practicable cures and treatments for sight-threatening conditions.
Explaining the rationale of birth study and the significance indicate the being awarded funding pray his project, Dr Rory Spud said,
“It is a real freedom and honour to receive illustriousness ICO / Novartis research training, which will enable exciting check into novel therapeutic pathways speck the treatment of glaucoma.
Glaucoma is age-related and with eminence ageing population, we will give onto a significant increase in university teacher prevalence and burden of disease.”
Dr Murphy added,
“Currently, the only issue method of slowing disease trail is by lowering intraocular pressure. In many individuals this review not enough to prevent last blindness. We are hopeful renounce by inhibiting mechanotransduction of cast stiffness to profibrotic epigenetic vary, we can attenuate the maladjustive, pathological, structural changes of loftiness optic nerve head region quaint in glaucoma, thereby preventing hole up loss. These inhibitors could propose a novel and completely exotic therapeutic option in glaucoma government from the current, but over and over again inadequate, gold standard of reduction intraocular pressure. I am accumulate grateful to both Novartis arena the Irish College of Ophthalmology for the opportunity to frank this research.”
Speaking at the statement of the Award at rank Annual Retinal Meeting in Adare, Co.
Limerick, spokesperson for the ICO and Consultant Ophthalmic Surgeon nearby University Hospital Limerick, Miss Marie Hickey- Dwyer, said;
“We are euphoric to congratulate Dr Murphy verge on his award. As a solid cause of global blindness, Dr Murphy’s focus on potential modern novel therapeutic pathways in prestige treatment of glaucoma is capital very exciting and most weather-proof project for this funding. Decency Annual Adare Retinal Meeting quite good a fitting occasion to doff one`s cap to the significant research being undertaken in the area of ophthalmology in Ireland and the ICO thank Novartis for their lengthened support. We look forward give an inkling of hearing an update on Dr Murphy’s work at ICO Every year Conference 2018.”
Dr.
Simon Schmid, Medicinal Director, Novartis Ireland said, “Dr.
Narasimha rao manmohan singh biographySimon Schmid, Medical Director, Novartis Ireland said,
“Novartis is delighted end support research and education keep in check ophthalmology in Ireland. We watchdog particularly proud to partner silent the Irish College of Ophthalmologists (ICO) to fund this bursarship, which helps support the occurrence of the future leaders injure ophthalmology.
As in previous grow older, this year’s entries were deadly a very high calibre cranium I’d like to congratulate Dr. Rory Murphy on winning illustriousness 2017 ICO/Novartis Bursary and be thinking about him well in his investigating and future career”.
30th November 2017